Literature DB >> 6248627

Possible role of an endogenous opiate in the cardiovascular effects of central alpha adrenoceptor stimulation in spontaneously hypertensive rats.

C Farsang, M D Ramirez-Gonzalez, L Mucci, G Kunos.   

Abstract

In unanesthetized sponatneously hypertensive rats (SHR), naloxone (0.5--2 mg/kg ip.) or naltrexone (2 mg/kg) inhibited the hypotension and bradycardia produced by clonidine (5--20 micrograms/kg iv.). Chronic treatment of SHR with clonidine (3 x 20 micrograms/kg/day orally for 12 days) reduced blood pressure and heart rate and these effects were acutely reversed by a single injection of naloxone. Naloxone also reversed the hypotension produced by a single injection of alpha-methyldopa (50--300 mg/kg ip.). In pentobarbital-anesthetized SHR, the hypotension and bradycardia produced by 5 micrograms/kg of clonidine were inhibited either by naloxone (2 mg/kg) or by yohimbine (1 mg/kg ip.). Morphine (0.33 mg/kg iv.) also reduced blood pressure and heart rate in these animals but these effects were only antagonized by naloxone and not by yohimbine. In conscious and anesthetized normotensive Wistar Kyoto rats, the reduction in blood pressure and heart rate by clonidine or alpha-methyldopa were smaller than in SHR, and these effects were not influenced by naloxone. These results confirm and extend earlier observations and suggest the existence of an "opioidergic" component in the antihypertensive action of central alpha adrenoceptor stimulants in SHR. They also show that a similar mechanism is either absent or inactive in the normotensive Wistar Kyoto rats.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6248627

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  14 in total

1.  Opiate receptors and the endorphin-mediated cardiovascular effects of clonidine in rats: evidence for hypertension-induced mu-subtype to delta-subtype changes.

Authors:  R Mosqueda-Garcia; G Kunos
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

Review 2.  Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity.

Authors:  Michael S Toce; Peter R Chai; Michele M Burns; Edward W Boyer
Journal:  J Med Toxicol       Date:  2018-10-30

3.  Plasma concentration and vascular effect of beta-endorphin in spontaneously hypertensive and Wistar Kyoto rats.

Authors:  B Bucher; R Bettermann; P Illes
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-04       Impact factor: 3.000

4.  Effect of clonidine on beta-endorphin, ACTH and cortisol secretion in essential hypertension and obesity.

Authors:  J Słowinska-Srzednicka; S Zgliczynski; P Soszynski; J Puciłowska; M Wierzbicki; W Jeske
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Potentiation by naloxone of pressor reflexes.

Authors:  J L Montastruc; P Montastruc; F Morales-Olivas
Journal:  Br J Pharmacol       Date:  1981-09       Impact factor: 8.739

6.  Alpha-methyldopa induces a naltrexone-insensitive antinociception and hypomotility in rats.

Authors:  P L van Giersbergen; E van Duinkerken; C G Sweep; V M Wiegant; J M van Ree; W de Jong
Journal:  Br J Pharmacol       Date:  1990-03       Impact factor: 8.739

7.  Reduction by phentolamine of the hypotensive effect of methionine enkephalin in anaesthetized rabbits.

Authors:  P J Eulie; H M Rhee
Journal:  Br J Pharmacol       Date:  1984-11       Impact factor: 8.739

8.  Interaction between clonidine and physostigmine in normal rats and in rats after sinoaortic denervation.

Authors:  C A Taira; M A Enero
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-05       Impact factor: 3.000

9.  Clonidine does not affect lidocaine seizure threshold in rats.

Authors:  M Yokoyama; M Hirakawa; H Goto
Journal:  Can J Anaesth       Date:  1993-12       Impact factor: 5.063

10.  Beta 2-adrenergic mechanisms in experimental arthritis.

Authors:  J D Levine; T J Coderre; C Helms; A I Basbaum
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.